Wegovy HD: what the STEP UP trial found

What Wegovy HD is

Semaglutide is a GLP-1 receptor agonist. At 0.5mg and 1mg weekly it is Ozempic, a diabetes drug. At 2.4mg weekly it is Wegovy, approved for obesity. At 7.2mg weekly it is Wegovy HD: the same molecule at three times the obesity dose.

The rationale is straightforward. Dose-response curves for GLP-1 drugs have not been flat at approved doses. Semaglutide keeps producing more weight loss as the dose goes up, at least through the ranges tested so far. Novo Nordisk bet that 7.2mg would add meaningful efficacy over 2.4mg, and the STEP UP trial confirmed that bet: 3.2 percentage points more weight loss in the same patient population over the same 72 weeks.

The drug received FDA approval on March 19, 2026, under the Commissioner's National Priority Voucher accelerated review process. Novo Nordisk launched it in the US in April 2026 in a single-dose pen. EU and UK regulatory decisions are expected in the second half of 2026.

What the STEP UP trial found

STEP UP was a phase 3b randomized, double-blind, placebo-controlled trial conducted across 95 sites in 11 countries. It enrolled 1,407 adults with obesity (BMI 30 or higher) and without type 2 diabetes, randomized 5:1:1 to semaglutide 7.2mg, semaglutide 2.4mg, or placebo for 72 weeks.

The 3.2-point gap between 7.2mg and 2.4mg is smaller than the gap between semaglutide and tirzepatide in earlier head-to-head data, but it is real and meaningful. At 200 lbs, that difference is 6 additional pounds. At 250 lbs, it is nearly 8. Not transformative on its own, but for patients who hit a plateau on standard Wegovy, that extra increment matters.

A separate STEP UP T2D arm enrolled approximately 500 adults with obesity plus type 2 diabetes. There, semaglutide 7.2mg produced 14.1% weight loss, lower than the non-diabetic arm as expected, but still meaningful given the metabolic headwinds T2D creates.

The side effect worth knowing about

The STEP UP safety data introduced something not prominent in earlier semaglutide trials: dysesthesia, which covers any altered skin sensation including tingling, numbness, or a burning feeling, usually in the hands or feet.

At the 7.2mg dose, 22% of participants reported it. At 2.4mg: 6%. Placebo: 0.3%. That jump from 6% to 22% is not a rounding error. It is a real signal tied to the higher dose.

In the trial, most cases were mild and reversible. The mechanism is not fully understood, but altered peripheral nerve sensation has been noted with other GLP-1 agonists at higher doses. If you are already managing any nerve-related condition or have diabetes-related neuropathy concerns, this is the specific question to raise before switching. For everyone else, it is worth knowing about rather than worrying about outright.

The remaining side-effect profile looks familiar: nausea, vomiting, constipation, and diarrhea at rates consistent with the GLP-1 class. Dose titration helps. Discontinuation rates due to GI adverse events were higher at 7.2mg than at 2.4mg but not dramatically so.

Wegovy HD vs tirzepatide: how close is close

Tirzepatide 15mg (the highest approved Zepbound dose) produced 20.9% mean weight loss at 72 weeks in the SURMOUNT-1 trial. Wegovy HD produced 20.7% at the same timepoint in STEP UP. Those numbers are essentially identical.

They are also from different trials with different patient populations, so reading too much into the 0.2-point gap is a mistake. Novo Nordisk has not run a head-to-head between Wegovy HD and tirzepatide. Until that trial exists, the honest comparison is: the numbers land in the same range, and any individual difference in outcomes will come from patient-specific response, tolerability, and cost.

The mechanism matters more than people give it credit for. Tirzepatide is a dual GLP-1 and GIP agonist. The GIP receptor amplifies the weight-loss effect and reduces nausea. Wegovy HD is still only GLP-1. It achieves similar aggregate numbers by pushing the dose higher rather than adding a second receptor. Whether that distinction produces different effects on body composition, metabolic markers, or long-term maintenance is not yet established.

What accelerated approval actually means

Wegovy HD received approval through the FDA's Commissioner's National Priority Voucher (CNPV) pilot program, which fast-tracks review for drugs aligned with critical US health priorities. Obesity qualifies. The accelerated path did not skip standard efficacy and safety review. The STEP UP data is the same data any approval would require.

What accelerated approval does require is a confirmatory post-market trial. Novo Nordisk is obligated to demonstrate, in a subsequent study, that the drug continues to meet its efficacy endpoints. This is standard procedure for accelerated approvals, not a workaround. The drug is approved and available. The confirmatory trial is an ongoing regulatory requirement, not a condition of access.

Patients should know that if the confirmatory trial shows problems, the FDA can require label changes or, in rare cases, withdraw approval. That is a theoretical risk worth understanding, not a reason to avoid the drug.

Who Wegovy HD is for

The clearest candidate is someone who responded well to semaglutide 2.4mg, tolerated it, lost weight, and then plateaued before reaching their goal. Wegovy HD offers an additional increment of efficacy within the same drug family, with no need to switch mechanisms or adjust to a different molecule.

It is not the obvious first choice for someone starting treatment from scratch. Standard Wegovy 2.4mg remains well-characterized. The dysesthesia signal at 22% is real and worth noting for new starters who have not established tolerability at lower doses. The typical path would be: titrate through standard doses, assess response, then step up to 7.2mg if the plateau is real and the goal is still unmet.

For people deciding between Wegovy HD and tirzepatide, the efficacy numbers are close enough that the decision usually comes down to tolerability and cost. Tirzepatide remains the stronger choice where preserving lean mass matters most, based on the existing body composition data from the SURMOUNT trials.

What to watch for

The confirmatory trial data will matter. If it shows consistent efficacy and a cleaner long-term picture for dysesthesia, it will determine how broadly Wegovy HD gets prescribed. Whether that 22% rate resolves with continued use, or whether it tracks with dose duration, is the key unanswered safety question.

EU and UK regulatory decisions are expected in the second half of 2026. Insurance coverage in the US is still settling. Medicare's GLP-1 coverage expansion starting July 2026 covers Wegovy (standard dose). Whether Wegovy HD earns the same coverage tier will depend on CMS formulary decisions that are not yet public.

The longer-term question is where Wegovy HD sits once retatrutide and CagriSema reach approval. Retatrutide's TRIUMPH trial posted 28.3% mean weight loss. If that drug clears the FDA, Wegovy HD's position as the high-efficacy semaglutide option will face real competition from above. For now, 20.7% weight loss puts it squarely in range with the current market leader.